Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Baxter to $48 from $50 and keeps an Outperform rating on the shares, which were also added to the firm’s "Tactical Outperform" list as the firm made a number of changes to its lists as part of its Q1 earnings preview for the MedTech, Life Science Tools and Diagnostics group.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BAX:
